Pfizer vaccine, children 5-11 years: new tests

Pfizer announces the launch of new tests to collect data on the efficacy and safety of the anti-Covid vaccine developed with the German BioNTech in children aged 5-11. “Phase 2/3 of our ongoing vaccine study in healthy children begins today,” tweets the US group. “This – explains Pfizer – is the next step that allows us to collect data to understand the safety and immunogenicity of the vaccine in the age group between 5 and 11 years”.